OrthoPediatrics Financials - Benzinga

OrthoPediatrics Corp

KIDSNASDAQ

Trade with Public

Trade with Public

$22.55

-0.09-0.4%

al cierre: Sep 25, 5:00 PM EST

$22.55

N/A

After hour: 4:00 PM EST

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

OrthoPediatrics Financials

OrthoPediatrics (KIDS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
OrthoPediatrics Q2 Adj. EPS $(0.26) Beats $(0.30) Estimate, Sales $70.508M Beat $68.247M Estimate

OrthoPediatrics (NASDAQ:KIDS) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 136.36 percent decrease over losses of $(0.11) per share from

Benzinga Newsdesk

PRO
OrthoPediatrics Raises FY2026 Sales Guidance from $263.000M-$267.000M to $265.000M-$269.000M vs $265.240M Est

OrthoPediatrics (NASDAQ:KIDS) raises FY2026 sales outlook from $263.000 million-$267.000 million to $265.000 million-$269.000 million vs $265.240 million estimate.

Benzinga Newsdesk

PRO
OrthoPediatrics Raises FY2026 Sales Guidance from $262.000M-$266.000M to $263.000M-$267.000M vs $264.310M Est

OrthoPediatrics (NASDAQ:KIDS) raises FY2026 sales outlook from $262.000 million-$266.000 million to $263.000 million-$267.000 million vs $264.310 million estimate.

Benzinga Newsdesk

PRO
OrthoPediatrics Q1 Adj. EPS $(0.42) Beats $(0.48) Estimate, Sales $59.362M Beat $58.315M Estimate

OrthoPediatrics (NASDAQ:KIDS) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 7.69 percent decrease over losses of $(0.39) per share from the

Benzinga Newsdesk

Earnings Scheduled For April 30, 2026

Benzinga Insights

PRO
OrthoPediatrics Sees FY2026 Sales $262.000M-$266.000M vs $263.431M Est

OrthoPediatrics (NASDAQ:KIDS) sees FY2026 sales of $262.000 million-$266.000 million vs $263.431 million analyst estimate.

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved